drugset
drugset / Trial / NCT03051087

To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®

NCT03051087 ↗

Phase 4 Completed 255 enrolled LG Life Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

to compare and evaluate the efficacy and safety of Ganilever PFS and Orgalutran® in infertility women for assisted reproductive technologies

Timeline

Start
2016-10
Primary completion
2018-03
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganirelix Protein / enzyme biologic 0.25 mg —

Indications

ovarian hyperstimulation syndrome